Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06443996
Other study ID # FDCRC97-MYL
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date December 31, 2027

Study information

Verified date May 2024
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational cohort study to explore the effects of sleep quality and mental status on early postoperative recurrence and prognosis in patients with colorectal cancer.


Description:

Evidence of evidence-based medicine shows that patients with malignant tumors have heavy psychological pressure after disease, and are prone to different degrees of sleep disorders and mental health problems, which often affect the progression and prognosis of the primary tumor. Previous studies have reported that baseline sleep quality was independently associated with risk of progression, risk of death, and response to treatment in patients with metastatic colorectal cancer before and during chemotherapy. Surgery, as a stressor, often causes obvious psychological stress reactions in patients, resulting in varying degrees of sleep disorders and poor mental performance, which may also become a factor affecting the recurrence and prognosis of patients. Therefore, the Department of Colorectal Surgery, Affiliated Cancer Hospital of Fudan University intends to conduct a prospective observational cohort study on the effects of sleep quality and mental state on early postoperative recurrence and prognosis of patients with colorectal cancer, in order to explore the effects of sleep quality and mental state on early postoperative recurrence and prognosis of patients with colorectal cancer.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Preoperative fibrocolonoscopy and pathological examination confirmed colorectal cancer; 2. Age 18 ~ 80 years old; 3. Baseline clinical stage TNM ? to ? : cT1-4N0-2M0 (AJCC-8 version); 4. The United States Eastern Oncology Consortium (ECOG) physical status score was 0 to 2 points; 5. Laboratory examination results before admission met the following surgical conditions: neutrophil (ANC) =1.5×109/L, platelets (PLT) = 100×109/L, total bilirubin (TBI) =1.5× upper limit of normal (2mg/dl), alanine aminotransferase (ALT), aspartate aminotransferase (AST) =2× upper limit of normal; Coagulation parameters in the normal range; 6. Able to complete the required research questionnaire independently or with the assistance of the researcher; 7. Patients were willing to undergo regular follow-up after surgery and had no psychological, family, social, or geographic constraints that affected protocol compliance and follow-up time; 8. Patients and their families can understand and are willing to participate in this clinical study, and sign informed consent. Exclusion Criteria: 1. Under 18 years of age or over 80 years of age; 2. Have a family history of severe mental illness; 3. People with mental illness or intellectual disability who cannot correctly describe their feelings; 4. The patient has severe systemic infection; 5. No radical operation was performed during the operation due to various reasons; 6. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery; 7. Merge other parts of the transfer; 8. Have serious heart, lung, liver and kidney diseases, can not tolerate surgery; 9. Active stage of liver disease or abnormal liver function, ALT, AST, TBIL is more than 2 times the upper limit of normal value; 10. Renal function damage, Cr = 2 times the upper limit of normal value or BUN = 2 times the upper limit of normal value; 11. The subject's blood white blood cells are lower than the lower limit of normal, or platelets are lower than the lower limit of normal, or there are other blood system diseases; 12. Severe coagulation mechanism disorder and bleeding tendency; 13. Serious uncontrolled medical disease, recent history of myocardial infarction (within 3 months); Acute infection; 14. Patients with uncontrolled severe hypertension and severe diabetes after intervention; 15. The researchers considered that other candidates were not suitable for inclusion in this study.

Study Design


Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ma Yanlei

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival (DFS) The duration between the date after surgery to the date of any recurrence or death firstly through study completion, an average of 1 year
Primary Overall Survival Time from the start of surgical randomization to death (from any cause) through study completion, an average of 1 year
Primary Effect of sleep quality and mental state on early recurrence and prognosis of patients with colorectal cancer after surgery The correlation of GAD-7 scale score, PHQ-9 scale score and ESAS scale score with Disease-free survival (DFS), Overall Survival and tumor-free survival rate of patients was analyzed through study completion, an average of 1 year
Secondary Tumor markers CEA, CA19-9 was used to determine recurrence in patients with colorectal cancer enrolled in the study. Tumor markers CEA, CA19-9 was used to determine recurrence in patients with colorectal cancer enrolled in the study. 1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months
Secondary Enteroscope was used to determine recurrence in patients with colorectal cancer enrolled in the study. Enteroscope was used to determine recurrence in patients with colorectal cancer enrolled in the study. 1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months
Secondary Physical examination was used to determine recurrence in patients with colorectal cancer Physical examination was used to determine recurrence in patients with colorectal cancer.1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A